CancerNetwork Members: Login | Register
Become a fan on  Facebook  Add us on  Google Plus Follow us on  Twitter Join us on LinkedIn Sign up for our Newsletters Subscribe to our RSS Feed

 

CancerNetwork SearchMedica Medline Drugs

Powered by SearchMedica

 
PUBLICATIONS
NEWS
PODCASTS
TOPICS
BLOGS
NURSES
PATIENTS
JOBS
CONFERENCES
CME
SUPPLEMENTS
 

Home » NEWS

Oncology NEWS International. Vol. 11 No. 8
Pages: 1  2  3  
Next
 

NCI Girds for Sharply Lower Budget Increases in FY 2004

August 1, 2002

BETHESDA, Maryland—Leaner times are in the offing for the National Institutes of Health (NIH), starting in the fall of 2003. The White House has told agency officials to expect President Bush to propose only a 2.2% increase for the NIH in his budget recommendations for fiscal year (FY) 2004. This figure is significantly lower than the 15.7% increase he asked Congress to approve for NIH in the FY 2003 budget, which begins October 1.

In seeking $27.335 billion for NIH in FY 2003, which included a 12.2% increase to $4.725 billion for the National Cancer Institute, Mr. Bush added his support to the congressional drive to double the NIH budget over 5 years. FY 2003 is the last year of that effort.

Funding the NIBIB

With creation of the National Institute of Biomedical Imaging and Bioengineering (NIBIB), a number of NIH institutes have transfered grants to it and will continue to do so. 

In FY 2002, NCI is transferring 61 grants totaling $21 million to the new institute, NCI director Dr. Andrew von Eschenbach told NCAB members. In FY 2003, NCI expects to transfer another 122 grants totaling $35 million as well as $25 million in cash to NIBIB. 

"The concept is that the new institute will focus exclusively on the development of technology, while we will continue to emphasize the application of imaging technology and bioengineering to oncology," he said.

In one of several presentations to the National Cancer Advisory Board (NCAB) on the budget situation, NCI director Andrew von Eschenbach, MD, expressed optimism that Congress will accept the President’s FY 2003 recommendation, but noted the impact of an essentially flat budget in FY 2004.

"We are beginning to pay a great deal of attention to the fact that this growth curve is going to ultimately flatten out," he said. "At present, the philosophy that is being discussed is to maintain commitment to the renewal of noncompeting awards."

During the current fiscal year, nearly half of NCI’s $4.2 billion dollar budget will go to fund 4,600 research grants, up from 4,300 in FY 2001, Dr. von Eschen-bach said. This number is estimated to include 1,288 competing awards, including 816 RO1 grants (which support a single, investigator-initiated project), of which 195 will go to first-time grantees, up from 182 in FY 2001.

The NCI director said the Institute expects to fund the top 22% of research projects approved by peer review committees as worthy of support. The cut-off percentage at which such grants are funded is referred to as the payline. "So, for 2002, we are well on target with regard to growth, and at the same time, we are beginning to look at the growth from the view of the challenges that will play out next year and the years after," Dr. von Eschenbach said.

The payline for research grants is determined each year by both the budget that Congress allocates to NCI and the number of research grants on the peer-reviewed list. "As you see the dollars rising in the extramural research budget, you don’t always see a concomitant rise in the payline," said Marvin R. Kalt, PhD, director of the Division of Extramural Activities. "What you see is a concomitant rise in the number of absolute awards, perhaps, or the average cost."

Pages: 1  2  3  
Next
 

Join the Conversation

Want to join the conversation? If you're a healthcare professional, we'd like to hear your comments. Just sign in or register today to become part of our growing, online community.






 
TOPIC INDEX

Cancer Types

 
  • Breast
  • Breast (HER2+)
  • Breast (Triple-Negative)
  • CML
  • Colorectal
  • Gastrointestinal
  • GIST
  • Genitourinary
  • Gynecologic
  • Head & Neck
  • Hematology
  • Kidney (Renal Cell)
  • Leukemia
  • Lung
  • Lymphoma
  • Melanoma
  • Multiple Myeloma
  • Ovarian
  • Prostate
  • Sarcoma

Supportive Care

More Topics

  • Bone Metastases
  • End-of-Life Care
  • Palliative Care
  • Ethics in Oncology
  • Practice Management
  • Practice & Policy


All Topics 


 
FROM PHYSICIANS PRACTICE
Key Differences between FQHCs and RHCs
Chastity Werner, RHIT, June 13, 2013
FQHCs and RHCs take up a unique niche among physician practices. And that affects compensation and billing.
Improving Care Coordination in Your Practice
Susanne Madden,  June 12, 2013
Practices are feverishly working to control the rising costs of healthcare - effective care coordination can help.
Refunding Overpayments: Two Options for Medical Practices
Ericka L. Adler,  June 12, 2013
Medicare and Medicaid providers must return overpayments once identified. Here are two different refund approaches for practices to consider when necessary.
Four Easy Ways to Boost Patient Time of Service Collections
Aubrey Westgate,  June 12, 2013
Simple ways your medical practice staff can increase the likelihood patients will pay when presenting for appointments.
iPad Alternatives for Mobile Physicians
Marisa Torrieri, June 11, 2013
As more physicians are seeing the merits of media tablets, the market is expanding, too.
 

 

 
MOST POPULAR
  • Most Popular
  • Most Emailed
  • Most Recent
  • Dermatologic Adverse Events Associated With Targeted Therapies
  • Papillary Thyroid Carcinoma
  • Robotic-Assisted Radical Prostatectomy: Who Is Benefiting?
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Lower Back Pain in an Elderly Man With a History of Localized Prostate Cancer
  • Cannabis Linked to Decreased Bladder Cancer Risk
  • Breast Cancer Screening, Risk, and Options for High-Risk Women
  • Recurrent Epithelial Ovarian Cancer: An Update on Treatment
  • Rising PSA Level in a 46-Year-Old Man
  • ASCO: Long-Term Tamoxifen Benefit for Breast Cancer Confirmed
  • Bladder Cancer Recurrence High, Better Follow-Up Care Needed
  • ASCO: Post-Surgery Surveillance Found Safe in Seminoma
  • Fertility Preservation in Women With Breast Cancer: Challenges and Opportunities
  • Addressing Fertility Concerns in Women Diagnosed With Breast Cancer: Will Serial Reserve Screening Help?
  • Postmenopausal Hormone Receptor–Positive Advanced Breast Cancer
Click here to subscribe to our newsletter


CancerNetwork on Facebook


CancerNetwork | ConsultantLive | Diagnostic Imaging | Musculoskeletal Network | OBGYN.net | PediatricsConsultantLive |
Physicians Practice | Psychiatric Times | SearchMedica | Medical Resources

© 1996 - 2013 UBM Medica LLC, a UBM company
Privacy Statement - Terms of Service - Advertising Information - Editorial Policy Statement - UBM Medica Network Privacy Policy